• Revolution Medicines recently reported positive Phase 3 RASolute 302 results for its RAS(ON) inhibitor daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, with data featured in the Plenary Session at the 2026 ASCO Annual Meeting and supported by a company webcast and NEJM publication.
• The company also highlighted that daraxonrasib delivered what it described as unprecedented overall survival benefit, reinforcing the potential importance of RAS-targeted therapies in a cancer setting with few effective options.
• We will now examine how daraxonrasib’s Phase 3 survival benefit in metastatic pancreatic cancer could reshape Revolution Medicines’ investment narrative.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

Revolution Medicines Investment Narrative Recap

To own Revolution Medicines today, you have to believe RAS(ON) inhibitors can translate into meaningful, durable franchises across multiple hard to treat cancers, starting with pancreatic. The positive Phase 3 RASolute 302 survival data for daraxonrasib materially strengthens the case for regulatory filings and potential first approval, which now looks like the key near term catalyst. The biggest risk remains the company’s heavy cash burn and lack of revenue, which amplifies execution risk around this first launch.

In this context, the recent FDA safe to proceed letter for expanded access to daraxonrasib in metastatic pancreatic cancer looks particularly important. It keeps the drug in front of clinicians ahead of any regulatory submission, while the company continues to absorb large operating losses and build out its commercial footprint. Together with the ASCO plenary and NEJM publication, this expanded access pathway ties directly into how quickly daraxonrasib could translate into a real commercial asset.

Yet investors should also weigh how sustained losses of over US$1,000,000,000 a year could interact with any delay or disappointment around daraxonrasib’s launch...

Revolution Medicines' narrative projects $1.0 billion revenue and $148.6 million earnings by 2029. This implies an earnings increase of about $1.25 billion from -$1.1 billion today.

Uncover how Revolution Medicines' forecasts yield a $133.70 fair value, a 12% downside to its current price.

Exploring Other Perspectives

Before this news, the most cautious analysts were modeling only about US$463.7 million in revenue and US$58.0 million in earnings by 2029, so if you share their concern that high 2026 operating expenses of US$1.6 billion to US$1.7 billion may delay any move toward positive earnings, this new pancreatic data could turn out to be either a needed proof point or a reminder of how wide opinions can be on Revolution Medicines’ path ahead.

Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Revolution Medicines research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Revolution Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revolution Medicines' overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.